Loading
A phase 2/3 trial testing Elenestinib in systemic mastocytosis, now recruiting.
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis is a phase 2/3 interventional study registered as NCT04910685, led by Blueprint Medicines, and recruiting on the registry. Official title: A Randomised, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis. Planned enrolment is 534 participants (estimated). The study started in 2021-11-30 and primary completion is expected in 2032-09-30. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Indolent and smouldering systemic mastocytosis, Systemic mastocytosis, Sanofi.
Shares Indolent and smouldering systemic mastocytosis, Systemic mastocytosis.
Shares Indolent and smouldering systemic mastocytosis, Systemic mastocytosis.
Shares Indolent and smouldering systemic mastocytosis, Systemic mastocytosis, Sanofi.
Shares Indolent and smouldering systemic mastocytosis, Systemic mastocytosis.
Shares Indolent and smouldering systemic mastocytosis, Systemic mastocytosis.
Shares Indolent and smouldering systemic mastocytosis, Systemic mastocytosis.
Shares Indolent and smouldering systemic mastocytosis, Systemic mastocytosis.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/